Cat.No. : CSC-RO0374 Host Cell: Ba/F3
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0374 |
| Description | This cell line is engineered to stably overexpress exogenous human FGFR3-TACC3 fusion protein. |
| Target Gene | FGFR3-TACC3 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | Ba/F3 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Growth Conditions | 37 °C, 5% CO2 |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Biosafety Level | 2 |
| Thawing & Subculturing Instructions | 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL. |
| Growth Properties | Suspension, round |
| Freeze Medium | Frozen with 70% medium, 20% FBS, 10% DMSO |
| Freezing Instructions | Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Fibroblast growth factor receptor 3 (FGFR3) is a tyrosine kinase frequently altered in bladder cancer and other malignancies, driving tumor growth through various mutations and gene fusions. One of the notable fusions is FGFR3-TACC3, which leads to constitutive activation of the FGFR3 signaling pathway, contributing to cancer progression. Researchers are actively investigating therapies to inhibit FGFR3 activity, including small molecule inhibitors and monoclonal antibodies. However, challenges like resistance to pan-FGFR inhibitors or limited efficacy of conventional antibodies persist, driving the development of innovative approaches such as bispecific antibodies targeting FGFR3 variants. These antibodies exhibit superior specificity and inhibition capabilities, blocking key oncogenic mechanisms in FGFR3-driven cancers.
Figure 1. The researchers employed the FGFR3-TACC3 stable cell line to assess the inhibitory effects of R3-Altibody on cell proliferation driven by FGFR3 variants. (Yang Y, et al., 2024)
Creative Biogene's Human FGFR3-TACC3 Stable Cell Line - BaF3 provides a reliable in vitro model for studying FGFR3 signaling and evaluating the efficacy of new therapeutic candidates. This cell line can be effectively used in drug screening or functional studies, offering a valuable tool for researchers targeting FGFR3-driven oncogenic pathways.
A: The Human FGFR3-TACC3 Stable Cell Line - BaF3 provides a unique platform to explore the functional interplay between FGFR3 and TACC3. By using this cell line, researchers can conduct experiments to understand how the interaction between these two proteins influences intracellular signaling pathways, particularly those involved in cell proliferation and survival. This knowledge can shed light on the mechanisms of oncogenesis and potentially lead to the identification of novel therapeutic targets for cancer treatment.
A: The Human FGFR3-TACC3 Stable Cell Line - BaF3 allows researchers to model the effects of FGFR3 mutations on cellular functions by providing a controlled environment where these mutations can be introduced and their phenotypic consequences analyzed. This cell line is particularly useful for studying the role of FGFR3 in centrosome clustering and ciliogenesis, which are critical for cell division and signaling, respectively. Understanding the impact of FGFR3 mutations on these processes can contribute to the development of targeted therapies for diseases associated with abnormal centrosome function or ciliogenesis.
A: Researchers can use the Human FGFR3-TACC3 Stable Cell Line - BaF3 to perform a variety of assays to assess the efficacy of FGFR3 inhibitors. These include cell viability assays, such as the sulforhodamine B assay, to measure the impact of inhibitors on cell growth; apoptosis assays to evaluate the induction of programmed cell death; and Western blotting or ELISA to quantify changes in phosphorylation levels of FGFR3 and downstream signaling molecules. These strategies provide a comprehensive approach to understanding the effectiveness of FGFR3 inhibitors in modulating cancer cell behavior.
A: The Human FGFR3-TACC3 Stable Cell Line - BaF3 can be used to model the effects of FGFR3 mutations that are known to cause skeletal disorders, such as achondroplasia and hypochondroplasia. By introducing specific mutations into the FGFR3 gene within this cell line, researchers can investigate how these mutations affect cellular processes related to bone growth and development. This can lead to a better understanding of the molecular basis of these disorders and inform the development of targeted therapies aimed at correcting the underlying cellular defects.
A: The Human FGFR3-TACC3 Stable Cell Line - BaF3 is well-suited for high-throughput screening efforts due to its ability to stably express FGFR3 and TACC3. Researchers can use this cell line to screen large compound libraries for molecules that can modulate FGFR3 activity, either by directly binding to the receptor or by affecting its downstream signaling partners. The identification of such modulators can lead to the development of new therapeutic agents for the treatment of diseases associated with FGFR3 dysregulation, including cancer and skeletal disorders.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Human FGFR3-TACC3 Stable Cell Line - BaF3 represents the FGFR3-TACC3 fusion, providing a precise model for studying this specific oncogenic driver. This targeted model is crucial for understanding the unique signaling pathways and cellular behaviors induced by the FGFR3-TACC3 fusion, which is associated with various cancers.
This cell line ensures consistent expression of the FGFR3-TACC3 fusion protein, allowing for stable and reliable experimental conditions. The Human FGFR3-TACC3 Stable Cell Line - BaF3 enables us to consistently reproduce results in studies focusing on the biological effects of this fusion protein.
Benefiting from the BaF3 cell line's characteristics, the Human FGFR3-TACC3 Stable Cell Line - BaF3 exhibits robust cellular performance and growth. This performance is advantageous for long-term studies and extensive experimental series, providing the resilience needed for comprehensive research.
The cell line is specifically designed for testing the responsiveness of the FGFR3-TACC3 fusion to therapeutic agents. The Human FGFR3-TACC3 Stable Cell Line - BaF3 allows for effective screening of potential drugs targeting this fusion, crucial for the development of targeted cancer therapies.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
